Inventor · disambiguated record
Dante D. Podesto
Also filed as: PODESTO DANTE D
6 granted patents·54 citations·filing 2016–2023
83Inventor score
Files withTHERAVANCE BIOPHARMA R&D IP LLC6
Top patents by PatentIndex Score
6 records- 0197US9725470B2Substituted naphthyridines as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Aug 8, 2017·27 cites·19 claims
- 0296US11780852B2Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrileTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Oct 10, 2023·3 cites·55 claims
- 0395US10028960B2Pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jul 24, 2018·18 cites·13 claims
- 0492US10947254B2Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrileTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 16, 2021·3 cites·56 claims
- 0589US12358931B23-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Jul 15, 2025·0 cites·5 claims
- 0689US11110095B2Pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Sep 7, 2021·3 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when Dante D. Podesto files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →